A 60-year-old woman taking apixaban (Eliquis) has a persistent cough that progressed from clear sputum to blood‑tinged sputum; what is the appropriate next step?

Immediate Evaluation for Hemoptysis in Anticoagulated Patient

This patient requires urgent clinical assessment to determine if the hemoptysis represents a minor self-limited bleed versus a potentially life-threatening hemorrhage, as apixaban significantly increases bleeding risk and the FDA label explicitly warns about hemoptysis as a sign of serious bleeding requiring immediate medical attention 1.

Critical Initial Assessment

The FDA label for Eliquis specifically lists "cough up blood or blood clots" as a warning sign requiring immediate medical attention 1. This patient's progression from clear to bloody sputum while on anticoagulation demands urgent evaluation to:

• Quantify the bleeding: Small streaks versus frank hemoptysis (>100 mL in 24 hours)
• Assess hemodynamic stability: Blood pressure, heart rate, oxygen saturation
• Evaluate for respiratory distress: Respiratory rate, work of breathing, hypoxemia
• Check for other bleeding sites: Examine for concurrent bleeding from gums, GI tract, or elsewhere

Risk Stratification for Apixaban-Related Bleeding

This 60-year-old woman has several concerning features:

• Age and renal function: While not yet 80, advancing age increases bleeding risk. Check serum creatinine immediately—if ≥1.5 mg/dL combined with age or weight factors, she may have excessive drug levels 1
• Drug interactions: Verify she's not taking NSAIDs, aspirin, SSRIs, or other medications that increase bleeding risk 1, 2
• Pulmonary complications: Apixaban-associated diffuse alveolar hemorrhage (DAH), though rare, can present with hemoptysis and rapidly progress to respiratory failure 3, 4

Immediate Management Algorithm

If Hemoptysis is Minor (streaks only) AND Patient is Stable:

• Do NOT automatically stop apixaban without assessing the underlying cause—stopping anticoagulation increases stroke risk 1
• Obtain chest X-ray urgently to rule out pneumonia, mass, or infiltrates
• Check CBC, renal function, and consider apixaban anti-Xa level if available 5
• Investigate alternative causes: infection, bronchitis, pulmonary embolism recurrence

If Hemoptysis is Moderate-to-Severe OR Patient Shows Any Instability:

• Hold apixaban immediately 1
• Obtain stat CBC, coagulation studies, renal function, chest imaging (CT if stable enough)
• Consider ICU-level monitoring
• Reversal agent consideration: For life-threatening bleeding, andexanet alfa can reverse apixaban's anticoagulant effect (400 mg IV bolus followed by 4 mg/min infusion for 2 hours) 6

Critical Diagnostic Considerations

Diffuse alveolar hemorrhage is a rare but serious complication of apixaban that can occur even after prolonged stable use 3. Warning signs include:

• Rapidly progressive dyspnea
• Bilateral ground-glass opacities on imaging
• Dropping oxygen saturation
• Hemosiderin-laden macrophages on bronchoalveolar lavage

The case report of an 80-year-old man on apixaban 2.5 mg twice daily who developed DAH after invasive procedures highlights that triggers (recent procedures, infections, drug interactions) can precipitate bleeding even in patients on stable long-term therapy 3.

Interstitial lung disease is another rare apixaban complication, though it typically presents with dyspnea rather than hemoptysis 4.

Common Pitfalls to Avoid

• Don't assume it's just bronchitis: Blood-tinged sputum in an anticoagulated patient requires imaging and laboratory evaluation
• Don't reflexively stop anticoagulation for minor bleeding: The FDA label emphasizes that stopping apixaban increases stroke risk 1. Balance bleeding severity against thromboembolic risk
• Don't miss drug interactions: 67% of apixaban drug interactions in pharmacovigilance databases were not well-described, with most adverse events being hemorrhagic 2
• Don't delay reversal in major bleeding: Andexanet alfa achieves >90% reversal of anti-Xa activity within minutes 6

Disposition Decision

Admit for observation and workup if:

• Recurrent hemoptysis
• Abnormal vital signs or oxygen requirement
• Abnormal chest imaging
• Renal dysfunction (CrCl <30 mL/min)
• Concurrent high-risk medications

Outpatient management only if:

• Single episode of minimal blood streaking
• Normal vital signs and oxygen saturation
• Clear alternative explanation (e.g., upper respiratory infection)
• Normal or near-normal renal function
• Reliable patient who can return immediately if bleeding worsens
• Close follow-up arranged within 24-48 hours